FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126055537> ?p ?o ?g. }

• W2126055537 endingPage "25268" @default.
• W2126055537 startingPage "25261" @default.
• W2126055537 abstract "We have evaluated the effect of ring size of gramicidin S analogs on secondary structure, lipid binding, lipid disruption, antibacterial and hemolytic activity. Cyclic analogs with ring sizes ranging from 4 to 14 residues were designed to maintain the amphipathic character as found in gramicidin S and synthesized by solid phase peptide synthesis. The secondary structure of these peptides showed a definite periodicity in β-sheet content, with rings containing 6, 10, and 14 residues exhibiting β-sheet structure, and rings containing 8 or 12 residues being largely disordered. Peptides containing 4 or 6 residues did not bind lipopolysaccharide, whereas longer peptides showed a trend of increasing binding affinity for lipopolysaccharide with increasing length. Destabilization of Escherichia coli outer membranes was only observed in peptides containing 10 or more residues. Peptides containing fewer than 10 residues were completely inactive and exhibited no hemolytic activity. The 10-residue peptide showed an activity profile similar to that of gramicidin S itself, with activity against Gram-positive and Gram-negative microorganisms as well as yeast, but also showed high hemolytic activity. Differential activities were obtained by increasing the size of the ring to either 12 or 14 residues. The 14-residue peptide showed no antibiotic activity but exhibited increased hemolytic activity. The 12-residue peptide lost activity against Gram-positive bacteria, retained activity against Gram-negative microorganisms and yeast, but displayed decreased hemolytic activity. Biological activities in the 12-residue peptide were optimized by a series of substitutions in residues comprising both hydrophobic and basic sites resulting in a peptide that exhibited activities comparable with gramicidin S against Gram-negative microorganisms and yeast but with substantially lower hemolytic activity. Compared with gramicidin S, the best analog showed a 10-fold improvement in antibiotic specificity for Gram-negative microorganisms and a 7-fold improvement in specificity for yeast over human erythrocytes as determined by a therapeutic index. These results indicate that it is possible to modulate structure and activities of cyclic gramicidin S analogs by varying ring sizes and further show the potential for developing clinically useful antibiotics based on gramicidin S. We have evaluated the effect of ring size of gramicidin S analogs on secondary structure, lipid binding, lipid disruption, antibacterial and hemolytic activity. Cyclic analogs with ring sizes ranging from 4 to 14 residues were designed to maintain the amphipathic character as found in gramicidin S and synthesized by solid phase peptide synthesis. The secondary structure of these peptides showed a definite periodicity in β-sheet content, with rings containing 6, 10, and 14 residues exhibiting β-sheet structure, and rings containing 8 or 12 residues being largely disordered. Peptides containing 4 or 6 residues did not bind lipopolysaccharide, whereas longer peptides showed a trend of increasing binding affinity for lipopolysaccharide with increasing length. Destabilization of Escherichia coli outer membranes was only observed in peptides containing 10 or more residues. Peptides containing fewer than 10 residues were completely inactive and exhibited no hemolytic activity. The 10-residue peptide showed an activity profile similar to that of gramicidin S itself, with activity against Gram-positive and Gram-negative microorganisms as well as yeast, but also showed high hemolytic activity. Differential activities were obtained by increasing the size of the ring to either 12 or 14 residues. The 14-residue peptide showed no antibiotic activity but exhibited increased hemolytic activity. The 12-residue peptide lost activity against Gram-positive bacteria, retained activity against Gram-negative microorganisms and yeast, but displayed decreased hemolytic activity. Biological activities in the 12-residue peptide were optimized by a series of substitutions in residues comprising both hydrophobic and basic sites resulting in a peptide that exhibited activities comparable with gramicidin S against Gram-negative microorganisms and yeast but with substantially lower hemolytic activity. Compared with gramicidin S, the best analog showed a 10-fold improvement in antibiotic specificity for Gram-negative microorganisms and a 7-fold improvement in specificity for yeast over human erythrocytes as determined by a therapeutic index. These results indicate that it is possible to modulate structure and activities of cyclic gramicidin S analogs by varying ring sizes and further show the potential for developing clinically useful antibiotics based on gramicidin S." @default.
• W2126055537 created "2016-06-24" @default.
• W2126055537 creator A5002752537 @default.
• W2126055537 creator A5003573061 @default.
• W2126055537 creator A5019557472 @default.
• W2126055537 creator A5040471850 @default.
• W2126055537 creator A5052295449 @default.
• W2126055537 creator A5066530115 @default.
• W2126055537 date "1996-10-01" @default.
• W2126055537 modified "2023-10-12" @default.
• W2126055537 title "Modulation of Structure and Antibacterial and Hemolytic Activity by Ring Size in Cyclic Gramicidin S Analogs" @default.
• W2126055537 cites W1018105914 @default.
• W2126055537 cites W1530751827 @default.
• W2126055537 cites W1887368236 @default.
• W2126055537 cites W1971637906 @default.
• W2126055537 cites W1974653071 @default.
• W2126055537 cites W1977844334 @default.
• W2126055537 cites W1980595924 @default.
• W2126055537 cites W1985943496 @default.
• W2126055537 cites W1988300031 @default.
• W2126055537 cites W1989306703 @default.
• W2126055537 cites W1993791807 @default.
• W2126055537 cites W1996701239 @default.
• W2126055537 cites W2003529335 @default.
• W2126055537 cites W2004632778 @default.
• W2126055537 cites W2005943723 @default.
• W2126055537 cites W2006215136 @default.
• W2126055537 cites W2006548058 @default.
• W2126055537 cites W2011602346 @default.
• W2126055537 cites W2016189866 @default.
• W2126055537 cites W2018984543 @default.
• W2126055537 cites W2026220836 @default.
• W2126055537 cites W2028893004 @default.
• W2126055537 cites W2035447184 @default.
• W2126055537 cites W2048128158 @default.
• W2126055537 cites W2049636688 @default.
• W2126055537 cites W2050510462 @default.
• W2126055537 cites W2053705741 @default.
• W2126055537 cites W2071507204 @default.
• W2126055537 cites W2083039164 @default.
• W2126055537 cites W2088848851 @default.
• W2126055537 cites W2095414784 @default.
• W2126055537 cites W2119519534 @default.
• W2126055537 cites W2123219111 @default.
• W2126055537 cites W2127206088 @default.
• W2126055537 cites W2131170296 @default.
• W2126055537 cites W2135634954 @default.
• W2126055537 cites W2142723880 @default.
• W2126055537 cites W2157086438 @default.
• W2126055537 cites W2317560037 @default.
• W2126055537 cites W2414293732 @default.
• W2126055537 cites W2432023240 @default.
• W2126055537 cites W35241519 @default.
• W2126055537 doi "https://doi.org/10.1074/jbc.271.41.25261" @default.
• W2126055537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8810288" @default.
• W2126055537 hasPublicationYear "1996" @default.
• W2126055537 type Work @default.
• W2126055537 sameAs 2126055537 @default.
• W2126055537 citedByCount "171" @default.
• W2126055537 countsByYear W21260555372012 @default.
• W2126055537 countsByYear W21260555372013 @default.
• W2126055537 countsByYear W21260555372014 @default.
• W2126055537 countsByYear W21260555372015 @default.
• W2126055537 countsByYear W21260555372016 @default.
• W2126055537 countsByYear W21260555372017 @default.
• W2126055537 countsByYear W21260555372018 @default.
• W2126055537 countsByYear W21260555372019 @default.
• W2126055537 countsByYear W21260555372020 @default.
• W2126055537 countsByYear W21260555372021 @default.
• W2126055537 countsByYear W21260555372022 @default.
• W2126055537 countsByYear W21260555372023 @default.
• W2126055537 crossrefType "journal-article" @default.
• W2126055537 hasAuthorship W2126055537A5002752537 @default.
• W2126055537 hasAuthorship W2126055537A5003573061 @default.
• W2126055537 hasAuthorship W2126055537A5019557472 @default.
• W2126055537 hasAuthorship W2126055537A5040471850 @default.
• W2126055537 hasAuthorship W2126055537A5052295449 @default.
• W2126055537 hasAuthorship W2126055537A5066530115 @default.
• W2126055537 hasBestOaLocation W21260555371 @default.
• W2126055537 hasConcept C134018914 @default.
• W2126055537 hasConcept C144464004 @default.
• W2126055537 hasConcept C178790620 @default.
• W2126055537 hasConcept C185592680 @default.
• W2126055537 hasConcept C2778754761 @default.
• W2126055537 hasConcept C2779025318 @default.
• W2126055537 hasConcept C2779281246 @default.
• W2126055537 hasConcept C2779380641 @default.
• W2126055537 hasConcept C2779650302 @default.
• W2126055537 hasConcept C2780104969 @default.
• W2126055537 hasConcept C2780378348 @default.
• W2126055537 hasConcept C2781338088 @default.
• W2126055537 hasConcept C41625074 @default.
• W2126055537 hasConcept C523546767 @default.
• W2126055537 hasConcept C54355233 @default.
• W2126055537 hasConcept C55493867 @default.
• W2126055537 hasConcept C71240020 @default.
• W2126055537 hasConcept C86803240 @default.
• W2126055537 hasConceptScore W2126055537C134018914 @default.

• next